PT3204417T - Bloqueio de cd73 - Google Patents
Bloqueio de cd73Info
- Publication number
- PT3204417T PT3204417T PT157783101T PT15778310T PT3204417T PT 3204417 T PT3204417 T PT 3204417T PT 157783101 T PT157783101 T PT 157783101T PT 15778310 T PT15778310 T PT 15778310T PT 3204417 T PT3204417 T PT 3204417T
- Authority
- PT
- Portugal
- Prior art keywords
- blockade
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062323P | 2014-10-10 | 2014-10-10 | |
| US201562118549P | 2015-02-20 | 2015-02-20 | |
| US201562133597P | 2015-03-16 | 2015-03-16 | |
| US201562188881P | 2015-07-06 | 2015-07-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3204417T true PT3204417T (pt) | 2020-10-08 |
Family
ID=54291300
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157783101T PT3204417T (pt) | 2014-10-10 | 2015-10-09 | Bloqueio de cd73 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10766966B2 (pt) |
| EP (2) | EP3736294A3 (pt) |
| JP (2) | JP7037359B2 (pt) |
| KR (1) | KR102536786B1 (pt) |
| CN (1) | CN106852149B (pt) |
| AU (2) | AU2015329982B2 (pt) |
| CA (1) | CA2957813A1 (pt) |
| DK (1) | DK3204417T3 (pt) |
| ES (1) | ES2821964T3 (pt) |
| IL (1) | IL250579B2 (pt) |
| MX (1) | MX2017004691A (pt) |
| PT (1) | PT3204417T (pt) |
| RU (1) | RU2746804C2 (pt) |
| SG (1) | SG11201701341UA (pt) |
| WO (1) | WO2016055609A1 (pt) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3204417T (pt) * | 2014-10-10 | 2020-10-08 | Innate Pharma | Bloqueio de cd73 |
| DK3218406T3 (da) | 2014-11-10 | 2021-06-21 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| JP6805142B2 (ja) | 2014-11-21 | 2020-12-23 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３に対する抗体およびその使用 |
| WO2016081746A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies comprising modified heavy constant regions |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| JP2019514844A (ja) | 2016-03-04 | 2019-06-06 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｃｄ７３抗体を用いた併用療法 |
| MX2018016364A (es) | 2016-06-20 | 2019-11-28 | Kymab Ltd | Anticuerpos anti-pd-l1. |
| WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| CN110072891A (zh) * | 2016-12-13 | 2019-07-30 | 安斯泰来制药株式会社 | 抗人cd73抗体 |
| KR20200108915A (ko) * | 2017-01-24 | 2020-09-21 | 아이-맵 바이오파마 유에스 리미티드 | 항-cd73 항체 및 이것의 사용 |
| MX2019010848A (es) | 2017-03-16 | 2019-10-30 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| US20210107989A1 (en) * | 2017-04-04 | 2021-04-15 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| EP3630830A1 (en) * | 2017-05-23 | 2020-04-08 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| US11312783B2 (en) * | 2017-06-22 | 2022-04-26 | Novartis Ag | Antibody molecules to CD73 and uses thereof |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019068907A1 (en) * | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| JP7383609B2 (ja) * | 2017-11-15 | 2023-11-20 | イナート・ファルマ・ソシエテ・アノニム | Ａｔｐ放出の効果の強力化 |
| JP2021509009A (ja) | 2017-11-30 | 2021-03-18 | ノバルティス アーゲー | Ｂｃｍａターゲティングキメラ抗原受容体及びその使用 |
| KR20200139153A (ko) | 2018-02-27 | 2020-12-11 | 인사이트 코포레이션 | A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘 |
| MX2020009366A (es) | 2018-03-09 | 2020-10-14 | Phanes Therapeutics Inc | Anticuerpos anti-cd73 y usos de los mismos. |
| BR112020017382A2 (pt) | 2018-03-09 | 2021-01-26 | Agenus Inc. | anticorpos anti-cd73 e métodos de uso dos mesmos |
| BR112020020826A2 (pt) | 2018-04-12 | 2021-01-19 | Bristol-Myers Squibb Company | Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1 |
| MA52940A (fr) | 2018-05-18 | 2021-04-28 | Incyte Corp | Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| WO2019243252A1 (en) | 2018-06-18 | 2019-12-26 | Innate Pharma | Compositions and methods for treating cancer |
| IL300821A (en) | 2018-07-05 | 2023-04-01 | Incyte Corp | Fused pyrazine derivatives as A2A/A2B inhibitors |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| CN111499747B (zh) * | 2019-01-11 | 2022-03-18 | 康诺亚生物医药科技（成都）有限公司 | 一种抗cd73单克隆抗体及其应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| MX2021012769A (es) * | 2019-04-23 | 2021-11-18 | Innate Pharma | Anticuerpos bloqueadores cd73. |
| TWI790445B (zh) * | 2019-06-06 | 2023-01-21 | 大陸商北京加科思新藥研發有限公司 | 對cd73具有特異性的結合分子及其用途 |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| PE20220708A1 (es) | 2019-09-06 | 2022-05-04 | Symphogen As | Anticuerpos anti-cd73 |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| EP4058150A2 (en) | 2019-11-15 | 2022-09-21 | Genzyme Corporation | Biparatopic cd73 antibodies |
| MX2022007575A (es) | 2020-01-03 | 2022-09-23 | Incyte Corp | Anticuerpos anti cumulo de diferenciacion 73 (cd73) y usos de estos. |
| EP4084870A1 (en) | 2020-01-03 | 2022-11-09 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| MX2022013250A (es) * | 2020-04-22 | 2022-11-14 | Akeso Biopharma Inc | Anticuerpo anti-cd73 y uso del mismo. |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| EP4169948A4 (en) * | 2020-06-22 | 2024-07-10 | Innovent Biologics Suzhou Co Ltd | ANTI-CD73 ANTIBODIES AND USE THEREOF |
| KR20230066317A (ko) * | 2020-07-10 | 2023-05-15 | 바이오몰레큘러 홀딩스 엘엘씨 | 사면체 항체 |
| EP4196500A2 (en) | 2020-08-13 | 2023-06-21 | Innate Pharma | Cancer treatment methods using anti-cd73 antibodies |
| EP4240491A1 (en) | 2020-11-06 | 2023-09-13 | Novartis AG | Cd19 binding molecules and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| KR20230157940A (ko) | 2020-12-29 | 2023-11-17 | 인사이트 코포레이션 | A2a/a2b 저해제, pd-1/pd-l1 저해제 및 항-cd73 항체를포함하는 병용 요법 |
| WO2022235569A1 (en) * | 2021-05-05 | 2022-11-10 | Corvus Pharmaceuticals, Inc. | Anti-cd73 compounds to treat oncovirus-positive cancers |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| WO2023206242A1 (zh) * | 2022-04-28 | 2023-11-02 | 江苏中新医药有限公司 | 无钩状效应的抗人cd73单克隆抗体 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| ATE483472T1 (de) | 2002-05-30 | 2010-10-15 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| JP4462964B2 (ja) * | 2003-03-10 | 2010-05-12 | 第一三共株式会社 | 癌特異的抗原を標的とした抗体 |
| RU2406760C3 (ru) | 2005-05-09 | 2017-11-28 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CA3018525C (en) | 2005-07-01 | 2023-08-01 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20090130092A1 (en) * | 2007-10-30 | 2009-05-21 | Pinsky David J | Nucleotide phosphate dissipation as a treatment for vascular disorders |
| DK2242773T3 (en) | 2008-02-11 | 2017-09-25 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| NZ717213A (en) | 2008-12-09 | 2017-10-27 | Genentech Inc | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL3279215T3 (pl) | 2009-11-24 | 2020-06-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| PL2506871T3 (pl) | 2009-11-30 | 2017-03-31 | Janssen Biotech, Inc | Przeciwciała ze zmutowanymi regionami Fc i utraconymi funkcjami efektorowymi |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| DK2654780T3 (en) | 2010-12-23 | 2017-04-10 | Janssen Biotech Inc | ACTIVE PROTEASE-RESISTANT ANTIBODY-FC MUTANTS |
| WO2012145493A1 (en) | 2011-04-20 | 2012-10-26 | Amplimmune, Inc. | Antibodies and other molecules that bind b7-h1 and pd-1 |
| CN103842030B (zh) | 2011-08-01 | 2018-07-31 | 霍夫曼-拉罗奇有限公司 | 使用pd-1轴结合拮抗剂和mek抑制剂治疗癌症的方法 |
| AU2013256802A1 (en) | 2012-04-30 | 2014-12-11 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| CN103278634B (zh) * | 2013-05-16 | 2015-01-07 | 中国科学院近代物理研究所 | Cd73作为肾透明细胞癌干细胞表面标志物的应用 |
| KR102256152B1 (ko) | 2013-12-12 | 2021-05-27 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | Ｐｄ-1 항체, 이의 항원 결합 단편, 및 이의 의약 용도 |
| WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| PT3204417T (pt) * | 2014-10-10 | 2020-10-08 | Innate Pharma | Bloqueio de cd73 |
| KR102554507B1 (ko) | 2015-07-24 | 2023-07-11 | 이나뜨 파르마 에스.에이. | 조직 침윤성 nk 세포를 검출하는 방법 |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
| EP3577138A1 (en) | 2017-02-06 | 2019-12-11 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| MX2021012769A (es) | 2019-04-23 | 2021-11-18 | Innate Pharma | Anticuerpos bloqueadores cd73. |
-
2015
- 2015-10-09 PT PT157783101T patent/PT3204417T/pt unknown
- 2015-10-09 US US15/517,991 patent/US10766966B2/en active Active
- 2015-10-09 WO PCT/EP2015/073370 patent/WO2016055609A1/en active Application Filing
- 2015-10-09 ES ES15778310T patent/ES2821964T3/es active Active
- 2015-10-09 DK DK15778310.1T patent/DK3204417T3/da active
- 2015-10-09 KR KR1020177011231A patent/KR102536786B1/ko active IP Right Grant
- 2015-10-09 MX MX2017004691A patent/MX2017004691A/es unknown
- 2015-10-09 EP EP20180074.5A patent/EP3736294A3/en active Pending
- 2015-10-09 JP JP2017518540A patent/JP7037359B2/ja active Active
- 2015-10-09 CN CN201580055012.7A patent/CN106852149B/zh active Active
- 2015-10-09 CA CA2957813A patent/CA2957813A1/en active Pending
- 2015-10-09 RU RU2017105119A patent/RU2746804C2/ru active
- 2015-10-09 SG SG11201701341UA patent/SG11201701341UA/en unknown
- 2015-10-09 AU AU2015329982A patent/AU2015329982B2/en active Active
- 2015-10-09 EP EP15778310.1A patent/EP3204417B1/en active Active
-
2017
- 2017-02-13 IL IL250579A patent/IL250579B2/en unknown
-
2020
- 2020-07-16 JP JP2020122032A patent/JP7132981B2/ja active Active
- 2020-09-02 US US17/009,817 patent/US11958907B2/en active Active
-
2021
- 2021-08-16 AU AU2021215306A patent/AU2021215306A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3736294A3 (en) | 2021-02-17 |
| CN106852149A (zh) | 2017-06-13 |
| IL250579A0 (en) | 2017-04-30 |
| WO2016055609A1 (en) | 2016-04-14 |
| RU2746804C2 (ru) | 2021-04-21 |
| CA2957813A1 (en) | 2016-04-14 |
| US11958907B2 (en) | 2024-04-16 |
| RU2017105119A3 (pt) | 2019-04-29 |
| AU2015329982A1 (en) | 2017-03-09 |
| BR112017006464A2 (pt) | 2018-01-30 |
| JP7132981B2 (ja) | 2022-09-07 |
| CN106852149B (zh) | 2021-08-27 |
| AU2021215306A1 (en) | 2021-09-16 |
| AU2015329982B2 (en) | 2021-05-20 |
| SG11201701341UA (en) | 2017-03-30 |
| ES2821964T3 (es) | 2021-04-28 |
| JP7037359B2 (ja) | 2022-03-16 |
| DK3204417T3 (da) | 2020-10-12 |
| US10766966B2 (en) | 2020-09-08 |
| EP3204417A1 (en) | 2017-08-16 |
| KR20170070077A (ko) | 2017-06-21 |
| US20180237536A1 (en) | 2018-08-23 |
| KR102536786B1 (ko) | 2023-05-26 |
| JP2020186244A (ja) | 2020-11-19 |
| IL250579B1 (en) | 2023-01-01 |
| RU2017105119A (ru) | 2018-11-12 |
| EP3736294A2 (en) | 2020-11-11 |
| US20200392243A1 (en) | 2020-12-17 |
| IL250579B2 (en) | 2023-05-01 |
| EP3204417B1 (en) | 2020-07-22 |
| MX2017004691A (es) | 2017-10-02 |
| JP2018502051A (ja) | 2018-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL250579A0 (en) | blocking cd73 | |
| AP2017009836A0 (en) | Aminopyridyloxypyrazole compounds | |
| GB201402431D0 (en) | Compounds | |
| GB201404987D0 (en) | Compounds | |
| GB201406591D0 (en) | Compounds | |
| HK1218859A1 (zh) | 組合物 | |
| HK1214967A1 (zh) | 組合物 | |
| SG11201704735WA (en) | Composition | |
| AP2017009778A0 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201403017D0 (en) | Composition | |
| HK1244432A1 (zh) | 組合物 | |
| GB201414910D0 (en) | Composition | |
| ZA201704464B (en) | Composition | |
| GB201403561D0 (en) | Composition | |
| GB201414555D0 (en) | Composition | |
| GB201410493D0 (en) | Composition | |
| GB201519442D0 (en) | Composition | |
| ZA201606127B (en) | Composition | |
| GB201420628D0 (en) | Composition | |
| GB201415483D0 (en) | Composition | |
| GB201404390D0 (en) | Composition | |
| GB201405361D0 (en) | Compounds | |
| GB201402648D0 (en) | Composition | |
| IL250781A0 (en) | preparation | |
| GB201503484D0 (en) | Composition |